Sauvie

Executive Summary

Sauvie is a San Francisco-based biotechnology company founded in 2021 that is developing a next-generation protein discovery platform combining computational intelligence with biologics and antibody engineering. The company aims to create a 'digital home' for biological intelligence, leveraging advanced computational methods to accelerate the discovery and design of novel therapeutic proteins. By operating at the intersection of antibodies, biologics, and AI-driven protein design, Sauvie seeks to address key bottlenecks in traditional protein engineering, potentially enabling faster and more efficient development of therapeutics. As a private, early-stage venture with no disclosed funding or pipeline, Sauvie represents a high-risk, high-reward opportunity in the rapidly evolving computational biology space. Its success hinges on the ability to validate its platform, attract partnerships with larger biopharma players, and secure additional capital to advance its technology.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q4 2026Platform Validation or Preclinical Data Readout40% success
• TBDPartnership with Biopharma Company35% success